Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 23;51(21):11634–11651. doi: 10.1093/nar/gkad907

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Inhibition of BRD4 suppressed meso-endodermal differentiation, while promoting the differentiation of cardiomyocytes in hESCs. (A and B) qPCR analysis of transcript levels of TBXT and MIXL1 in early mesoderm (A), and MESP1 and TBX6 in late mesoderm (B) differentiated from hESCs following inhibition of BRD4 with 50 nM JQ1. (C) Transcript levels of SOX17 in endoderm differentiated from hESCs following inhibition of BRD4 with 10 or 50 nM JQ1, or 1 nM ARV-825. (D) Western blot analysis of SMAD2 and p-SMAD2 protein levels in hESCs cultured in E8 medium following inhibition of BRD4 with 50 nM JQ1 or 1 nM ARV-825 for 2 days. (Eand F) qPCR analysis of transcript levels of TGF-β pathway-associated genes (E), and WNT3 and WNT3A (F) in hESCs cultured in E8 medium following inhibition of BRD4 with 50 nM JQ1 for 2 days. (G) qPCR analysis of the transcript levels of TNNT2 and NKX2.5 in cardiomyocytes derived from hESCs following treatment with 10 μM I-BRD9, 2.5 μM IWP2 or a combination of both. (H) FACS analysis of TNNT2-positive cells in cardiomyocyte differentiation of hESCs following treatment with 10 μM I-BRD9, 2.5 μM IWP2 or a combination of both. (I and J) qPCR analysis of the transcript levels of TNNT2 (I) and NKX2.5 (J) in cardiomyocytes derived from hESCs following treatment with 2.5 μM IWP2, 1 nM ARV-825 or a combination of both.